A phase II multicenter trial of hyperCVAD MTX/Ara-C and rituximab in patients with previously untreated mantle cell lymphoma; SWOG 0213

BACKGROUND: Rituximab-hyper-CVAD alternating with rituximab-high-dose methotrexate and cytarabine is a commonly utilized regimen in the United States for mantle cell lymphoma (MCL) based on phase II single institutional data. To confirm the clinical efficacy of this regimen and determine its feasibi...

Descripció completa

Guardat en:
Dades bibliogràfiques
Autors principals: Bernstein, S. H., Epner, E., Unger, J. M., LeBlanc, M., Cebula, E., Burack, R., Rimsza, L., Miller, T. P., Fisher, R. I.
Format: Artigo
Idioma:Inglês
Publicat: Oxford University Press 2013
Matèries:
Original Articles
Accés en línia:https://ncbi.nlm.nih.gov/pmc/articles/PMC3660082/
https://ncbi.nlm.nih.gov/pubmed/23504948
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1093/annonc/mdt070
Etiquetes: Afegir etiqueta
Sense etiquetes, Sigues el primer a etiquetar aquest registre!

Ítems similars